At the 65th annual American Crystallographic Association 2015 meeting in Philadelphia this week, a team from the Rockville, Md.-based National Cancer Institute presented three newly determined crystal structures that collectively provide a starting point for a drug-design effort to combat MERS.
The researchers anticipate it will take at least a year to sort through the data and begin the actual drug design. However, this method could lead to a drug that is easily administered orally, a stumbling block that has limited the appeal of other types of antiviral medications developed for the same purpose.
More articles on infection control:
46 hospitals with the fastest patient aid
Infection preventionists approve 11 C. diff prevention recommendations
US News names Best Hospitals: 6 things to know